Search News Archives
Special Offers and Promotions
Brochures & Literature
Conferences | Events
Isogenic Panels of Neuronal iPSC Derivatives
AMSBIO announces the launch of a new range of induced pluripotent stem cell (iPSC) derived neural stem cells (NSCs) and neural lineage progenitors.
For several years, neuroscience research using cell line and animal models of degenerative neurological disorders such as Parkinson’s and Alzheimer’s disease has been challenged to translate results into in vivo conditions, whether for basic understanding of disease pathology or for the screening of targeted drug therapies. The development of iPSC technology and its further differentiation into various lineages, especially neuronal lineage cells and dopaminergic neurons, has overcome a major bottleneck by providing biologically relevant in vitro models to screen drugs for neuroprotection and movement-disorder therapy.
AMSBIO now offers isogenic panels of neuronal derivatives from these iPSCs, including neural stem cells, dopaminergic neurons, astrocytes and mixed neurons, allowing comparative neuroscience studies, and drug and toxicity screening.
These cell lines from multiple donors have been derived using integration-free, proprietary neural induction protocols, and are fully characterized for markers and normal karyotype. Validated for generating CRISPR-Cas9-engineered iPSC-lines for disease modelling these cells offer for flexibility in choosing the lineage most appropriate for research studies.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.